Analysts Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $11.45

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.27.

Several research firms have issued reports on HCAT. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Stephens raised their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada cut their price objective on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday, January 15th.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares in the company, valued at $998,613. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the transaction, the insider now directly owns 236,950 shares in the company, valued at $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,169 shares of company stock worth $639,174 over the last ninety days. Insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HCAT. First Light Asset Management LLC boosted its holdings in shares of Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. Impax Asset Management Group plc lifted its holdings in Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares during the period. Millennium Management LLC grew its position in shares of Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Health Catalyst by 1.1% during the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after buying an additional 25,000 shares during the period. Finally, Daventry Group LP raised its holdings in shares of Health Catalyst by 3.9% during the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after acquiring an additional 84,178 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $5.49 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a fifty-two week low of $5.35 and a fifty-two week high of $10.99. The stock has a market cap of $334.07 million, a PE ratio of -4.07 and a beta of 1.36. The stock has a fifty day moving average of $7.56 and a 200-day moving average of $7.53.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the business earned ($0.22) EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities research analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.